Survey Finds GLP-1 Drugs May Curb Drinking for Many Patients

A survey published Friday, October 30, in JAMA suggests that GLP-1 receptor agonist drugs, which are widely prescribed for type 2 diabetes and obesity, may also be linked to lower alcohol use in many patients.

The survey found that 44% of more than 200 participants who were drinking when they started a GLP-1 medication said they reduced their alcohol consumption during the first three months of treatment. The results were based on self-reports from adults who were already taking the drugs, not on a randomized clinical trial, and the data do not show that the medicines directly caused the change.

Even so, the findings add to growing interest in whether this class of drugs may affect more than blood sugar control and weight. Researchers said a possible explanation is that activation of the GLP-1 receptor may alter the brain’s reward systems in ways that reduce the desire to drink alcohol. That idea remains a hypothesis and will need stronger clinical evidence.

The report points to a possible new avenue for research into alcohol use disorder, a condition for which treatment options remain limited and relapse rates are high. If the effect seen in the survey holds up in controlled studies, doctors and researchers may begin to examine whether GLP-1 medicines could play a role in reducing cravings or drinking levels in some patients. The JAMA article said further investigation is needed to confirm both effectiveness and safety for that use.

The survey’s limits are significant. Because the responses were self-reported, the data may reflect recall errors or personal expectations about the drugs. The study design also cannot rule out other reasons for lower drinking, including changes in diet, broader health goals, medical advice, or reduced interest in alcohol during weight-loss treatment. Without a comparison group and formal tracking over time, the findings should be treated as preliminary.

Still, the report adds to a broader medical debate about whether medicines first developed for metabolic disease could be repurposed for behavioral health conditions. Researchers have increasingly looked at how established drugs might be used in new ways, especially when they appear to affect appetite, impulse control, or reward-related behavior. In that context, the survey may help guide future clinical trials designed to test alcohol outcomes more rigorously.

The findings could also matter beyond medicine. If larger studies eventually confirm that some patients drink less while taking GLP-1 drugs, the change could become a factor in alcohol demand, particularly for wine, beer, and spirits consumed by people using the treatments for obesity or diabetes. Any such effect remains uncertain for now, but the possibility is likely to draw attention from beverage companies, retailers, and market analysts already tracking how these drugs may change consumer habits.

For now, the JAMA report does not establish a new treatment standard. It offers an early signal that many patients noticed less drinking after starting a GLP-1 medication, while leaving open the central question of whether the drugs themselves are responsible.